During the pre-2022 timeframe, OPDIVO, developed through strategic collaboration between Ono Pharmaceutical and Bristol Myers Squibb, faced unprecedented competitive pressures within Japan's rapidly evolving oncology treatment landscape. The therapeutic agent experienced substantial market share erosion as KEYTRUDA vs OPDIVO competitive dynamics reached unprecedented intensity levels, with...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Português
Ελληνικά
Tiếng Việt